Cargando…
Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
LESSONS LEARNED. Definitive concurrent chemoradiotherapy based on oxaliplatin and endostatin was effective with the objective response rate exceeding 80%, and the treatment‐related toxicities were acceptable. The treatment compliance of the current combination was much higher, without significant re...
Autores principales: | Li, Wenxin, Chen, Peng, Zhang, Ni, Song, Tao, Wu, Shixiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459259/ https://www.ncbi.nlm.nih.gov/pubmed/30850562 http://dx.doi.org/10.1634/theoncologist.2019-0119 |
Ejemplares similares
-
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022) -
Single‐Agent Versus Double‐Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial
por: Zhao, Zhenhuan, et al.
Publicado: (2020) -
A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021) -
Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
por: Akahori, Takahiro, et al.
Publicado: (2019) -
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
por: Araujo‐Mino, Emilio P., et al.
Publicado: (2017)